Cargando…
Targeting immunosuppression by TGF-β1 for cancer immunotherapy
The TGF-β1 cytokine is a key mediator of many biological processes. Complex regulatory mechanisms are in place that allow one single molecule to exert so many distinct indispensable activities. The complexity of TGF-β1 biology is further illustrated by the opposing dual roles it plays during cancer...
Autores principales: | de Streel, Grégoire, Lucas, Sophie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Science
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8484859/ https://www.ncbi.nlm.nih.gov/pubmed/34302795 http://dx.doi.org/10.1016/j.bcp.2021.114697 |
Ejemplares similares
-
Therapeutic activity of GARP:TGF-β1 blockade in murine primary myelofibrosis
por: Lecomte, Sara, et al.
Publicado: (2023) -
Combined Blockade of GARP:TGF-β1 and PD-1 Increases Infiltration of T Cells and Density of Pericyte-Covered GARP(+) Blood Vessels in Mouse MC38 Tumors
por: Bertrand, Charlotte, et al.
Publicado: (2021) -
TGF-β in T Cell Biology: Implications for Cancer Immunotherapy
por: Dahmani, Amina, et al.
Publicado: (2018) -
Selective inhibition of TGF-β1 produced by GARP-expressing Tregs overcomes resistance to PD-1/PD-L1 blockade in cancer
por: de Streel, Grégoire, et al.
Publicado: (2020) -
Tumor in the Crossfire: Inhibiting TGF-β to Enhance Cancer Immunotherapy
por: Tschernia, Nicholas P., et al.
Publicado: (2022)